Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
Tully, D.C., Liu, H., Chatterjee, A.K., Alper, P.B., Epple, R., Williams, J.A., Roberts, M.J., Woodmansee, D.H., Masick, B.T., Tumanut, C., Li, J., Spraggon, G., Hornsby, M., Chang, J., Tuntland, T., Hollenbeck, T., Gordon, P., Harris, J.L., Karanewsky, D.S.(2006) Bioorg Med Chem Lett 16: 5112-5117
- PubMed: 16876402 
- DOI: https://doi.org/10.1016/j.bmcl.2006.07.033
- Primary Citation of Related Structures:  
2HH5, 2HHN - PubMed Abstract: 
The synthesis and structure-activity relationship of a series of arylaminoethyl amide cathepsin S inhibitors are reported. Optimization of P3 and P2 groups to improve overall physicochemical properties resulted in significant improvements in oral bioavailability over early lead compounds. An X-ray structure of compound 37 bound to the active site of cathepsin S is also reported.
Organizational Affiliation: 
Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Dr., San Diego, CA 92121, USA. dtully@gnf.org